Trial of Vinflunine Versus Alkylating Agent in Metastatic Breast Cancer

• ClinicalTrials.gov Identifier: NCT01091168
• Recruitment Status: Completed
• First Posted: March 23, 2010
• Results First Posted: September 16, 2019
• Last Update Posted: September 16, 2019
• Sponsor: Pierre Fabre Medicament
• Information provided by (Responsible Party): Pierre Fabre Medicament

Tracking Information

• First Submitted Date: February 3, 2010
• First Posted Date: March 23, 2010
• Results First Submitted Date: May 27, 2019
• Results First Posted Date: September 16, 2019
• Last Update Posted Date: September 16, 2019
• Actual Study Start Date: July 2009
• Actual Primary Completion Date: August 27, 2012 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: August 9, 2019)

Overall Survival [ Time Frame: From baseline up to 3 years 1 month ]

The main endpoint of this study is overall survival defined as the time from randomisation to the date of death or last follow-up. For patients who have not died, survival duration will be censored at the date of last contact or last follow-up or the date of last news.

• Original Primary Outcome Measures (submitted: March 19, 2010): Overall survival [ Time Frame: monthly for 6 months after disease progression and then every 3 months ]

Current Secondary Outcome Measures (submitted: August 9, 2019)

• Disease Control Rate (DCR) [ Time Frame: From baseline up to 3 years 1 month ]
  DCR was defined as the proportion of patients with Complete Response (CR), Partial Response (PR) and stable disease (SD), relative to the total number of patients in the analysed population.
• Progression Free Survival (PFS) [ Time Frame: From baseline to cut-off date(27 August 2012), up to 3 years ]
  PFS was defined as the time from randomisation to the first tumour progression or death due to any cause in the absence of previous documentation of objective tumour progression. PFS was performed in the ITT and eligible populations every 6 weeks based on RECIST version 1.1. For patients lost of follow up, or without a known record of progression or death, PFS was censored at the date of last tumour assessment or the date of last contact of a follow-up showing no progression which ever occured last.

Original Secondary Outcome Measures (submitted: March 19, 2010)

• Quality of life questionnaire [ Time Frame: every 6 weeks ]
• Adverse event profile [ Time Frame: monthly ]
• Tumour response rate [ Time Frame: every 6 weeks until disease progression ]
• Progression free survival [ Time Frame: every 6 weeks until disease progression ]

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Trial of Vinflunine Versus Alkylating Agent in Metastatic Breast Cancer
• Official Title: Phase III Trial of IV Vinflunine Versus an Alkylating Agent in Patients With Metastatic Breast Cancer Previously Treated With or Resistant to an Anthracycline, a Taxane, an Antimetabolite, and a Vinca-alkaloid (Study L00070 IN 308 B0)
• Brief Summary: In metastatic breast cancer (MBC) patients who have already received anthracyclines, taxanes, antimetabolites and vinca-alkaloids and have developed drug resistance to these drugs, therapeutic options are very limited. Alkylating agents showed a modest activity in pretreated metastatic breast cancer. This phase III trial will compare the effectiveness and the safety profile of vinflunine to an alkylating agent of physician choice in MBC patients who have exhausted anthracyclines, taxanes, antimetabolites and vinca-alkaloids.

Detailed Description

Breast cancer is the most frequently diagnosed cancer in women worldwide and the second leading cause of cancer-related deaths in women.

Patients with metastatic breast cancer (MBC) remains incurable, and current goals of therapy are to ameliorate symptoms, delay disease progression, improve or at least maintain quality of life (QoL), and prolong overall survival (OS).There are a number of agents with established single-agent activity, with the anthracyclines and taxanes considered generally the most active. In addition, several drugs with different mechanisms of action such as antimetabolites and vinca-alkaloids have also demonstrated substantial activity in the metastatic setting as single-agents or in combination.

In patients who progress after having received anthracyclines, taxanes, antimetabolites and vinca- alkaloids, therapeutic options are scarce. In this heavily pretreated population for whom overall survival is not expected to exceed 6 to 7 months, there is a clear need for novel therapies.

Vinflunine (VFL) is a microtubule inhibitor obtained by semi-synthesis, interacts with tubulin at the vinca-binding domain and inhibits tubulin assembly by perturbing microtubule dynamics and mitotic spindles without affecting assembled microtubules. VFL antitumour activity was fully demonstrated against a large and varied panel of murine and xenograft models.

The main haematological toxicity reported was the neutropenia Grade 3-4 (40-50%). The incidence of its complications (febrile neutropenia and neutropenic infection) was less than 8%. The main non-haematological toxicity Grade 3-4 (with an incidence more than 10%) reported were constipation and fatigue.

This was a prospective multicentre, open-label, randomised (1:1), phase III study comparing OS in patients treated with vinflunine versus those treated with an alkylating agent of physician's choice as third line treatment or more for patients with locally recurrent and/or metastatic breast cancer previously treated with and no longer candidate to anthracyclines, antimetabolites, taxanes and vinca- alkaloids..

The primary endpoint for the trial was OS. Patients were assessed for toxicity, tumour response and progression and status (alive-dead) at regular intervals during the study treatment and the follow-up period. Patients were treated until disease progression, unacceptable toxicity, patient or investigator's decision. After the study treatment discontinuation, patients were followed until death.

The VFL dose of 280 mg/m² was the selected dose for this phase III study in patients with heavily pre- treated MBC. Indeed, VFL dose was reduced from 320 to 280 mg/m² in advanced transitional cell carcinoma of urothelial tract patients with performance status (PS) of 1 or with PS of 0 and having received prior pelvic irradiation. This dose was more regularly tolerable in patients with advanced disease stage who were heavily pre-treated.

• Study Type: Interventional
• Study Phase: Phase 3
• Study Design: Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: None (Open Label); Primary Purpose: Treatment

Condition

• Breast Cancer
• Metastases

Intervention

• Drug: vinflunine
  280 mg/m2 on day 1 of each cycle every 3 weeks
  Other Names:

  • JAVLOR
  • L00070
• Drug: Alkylating agent of physician choice registered in cancer
  cyclophosphamide or melphalan or mitomycin C or thiotepa or cisplatin or carboplatin
  Other Name: Various

Study Arms

• Experimental: arm A: Vinflunine
  Patients randomised in the test arm (arm A) received VFL at the dose of 280 mg/m² on day 1 of each cycle every 3 weeks, over a 20-minute intravenous (IV) infusion. Cycles were repeated every 3 weeks.
  Intervention: Drug: vinflunine
• Active Comparator: arm B: Alkylating agent of physician choice
  Patients randomised in the control arm (arm B) received an alkylating agent used as a single agent which was available in the investigational center and was approved for the treatment of cancer in the country.
  Intervention: Drug: Alkylating agent of physician choice registered in cancer

• Publications *: Cortes J, Perez-Garcia J, Levy C, Gomez Pardo P, Bourgeois H, Spazzapan S, Martinez-Janez N, Chao TC, Espie M, Nabholtz JM, Gonzalez Farre X, Beliakouski V, Roman Garcia J, Holgado E, Campone M. Open-label randomised phase III trial of vinflunine versus an alkylating agent in patients with heavily pretreated metastatic breast cancer. Ann Oncol. 2018 Apr 1;29(4):881-887. doi: 10.1093/annonc/mdy051.

Recruitment Information

• Recruitment Status: Completed
• Actual Enrollment (submitted: November 22, 2011): 594
• Original Estimated Enrollment (submitted: March 19, 2010): 586
• Actual Study Completion Date: January 2014
• Actual Primary Completion Date: August 27, 2012 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:(main conditions)

• Female patients 18 to 75 years of age with metastatic breast cancer histologically/cytologically confirmed not amenable to curative surgery or radiotherapy and who have received at least two prior chemotherapy regimens including anthracyclines,taxanes,antimetabolite and vinca-alkaloid and are no longer candidate for these drugs,
• Karnofsky performance score of at least 70 %, adequate haematological, hepatic and renal functions and ECG without clinically relevant abnormality.

Exclusion Criteria:

• Concurrent serious uncontrolled medical disorder,
• known or clinical evidence of brain metastases or leptomeningeal involvement,
• pulmonary lymphangitis or symptomatic pleural effusion or symptomatic ascites,
• history of second primary malignancy,
• HIV infection, preexisting neuropathy,
• pregnancy or breast feeding.

Sex/Gender

• Sexes Eligible for Study: Female

• Ages: 18 Years to 75 Years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: Argentina, Austria, Belarus, Belgium, France, Germany, Italy, Portugal, Russian Federation, South Africa, Spain, Taiwan, Ukraine, United Kingdom

Administrative Information

• NCT Number: NCT01091168
• Other Study ID Numbers: L00070 IN 308 B0
• Has Data Monitoring Committee: Yes
• U.S. FDA-regulated Product: Not Provided
• IPD Sharing Statement: Not Provided
• Current Responsible Party: Pierre Fabre Medicament
• Original Responsible Party: Maud BRANDELY, MD, Pierre Fabre Medicament
• Current Study Sponsor: Pierre Fabre Medicament
• Original Study Sponsor: Same as current
• Collaborators: Not Provided

Investigators

• Study Director: Karim Keddad, MD, PhD; Institut de Recherche Pierre Fabre

• PRS Account: Pierre Fabre Medicament
• Verification Date: August 2019